# VB15010

Source: https://onco.cc/drugs/vb15010/  
OnCo record `vb15010` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VB15010 is a small-molecule inhibitor from Zhejiang Yangli Pharmaceutical Technology Co., Ltd., in registered phase 2 trials for ovarian cancer, prostate cancer, pancreatic ductal adenocarcinoma.

## Summary

VB15010 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Zhejiang Yangli Pharmaceutical Technology Co., Ltd., in ovarian cancer, prostate cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, colorectal cancer. Described in the registry record as a oral parp1 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: VB15010
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a oral parp1 inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of VB15010: https://clinicaltrials.gov/search?intr=VB15010

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- trials: [Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06819215/)

---
JSON: https://onco.cc/api/v1/entities/vb15010.json